Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The company’s AN9025 will shortly enter phase 1.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
But the group still hopes to get IGV-001 approved based on overall survival data.
A more comprehensive dataset on JANX007 sends the group’s stock down.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
